Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing
Top Cited Papers
Open Access
- 2 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (9), 2459-2468
- https://doi.org/10.1093/cid/ciaa530
Abstract
To explore and describe the current literature surrounding bacterial/fungal co-infection in patients with coronavirus infection. MEDLINE, EMBASE, and Web of Science were searched using broad based search criteria relating to coronavirus and bacterial co-infection. Articles presenting clinical data for patients with coronavirus infection (defined as SARS-1, MERS, SARS-COV-2, and other coronavirus) and bacterial/fungal co-infection reported in English, Mandarin, or Italian were included. Data describing bacterial/fungal co-infections, treatments, and outcomes were extracted. Secondary analysis of studies reporting antimicrobial prescribing in SARS-COV-2 even in the absence of co-infection was performed. 1007 abstracts were identified. Eighteen full texts reported bacterial/fungal co-infection were included. Most studies did not identify or report bacterial/fungal coinfection (85/140;61%). 9/18 (50%) studies reported on COVID-19, 5/18 (28%) SARS-1, 1/18 (6%) MERS, and 3/18 (17%) other coronavirus. For COVID-19, 62/806 (8%) patients were reported as experiencing bacterial/fungal co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacterial coinfection. On secondary analysis, 1450/2010 (72%) of patients reported received antimicrobial therapy. No antimicrobial stewardship interventions were described. For non-COVID-19 cases bacterial/fungal co-infection was reported in 89/815 (11%) of patients. Broad-spectrum antibiotic use was reported. Despite frequent prescription of broad-spectrum empirical antimicrobials in patients with coronavirus associated respiratory infections, there is a paucity of data to support the association with respiratory bacterial/fungal co-infection. Generation of prospective evidence to support development of antimicrobial policy and appropriate stewardship interventions specific for the COVID-19 pandemic are urgently required.Keywords
Funding Information
- Centre for Antimicrobial Optimisation at Imperial College London
This publication has 47 references indexed in Scilit:
- Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trialThe Lancet Infectious Diseases, 2016
- Understanding the mechanisms and drivers of antimicrobial resistanceThe Lancet, 2016
- Isolated Candida infection of the lungRespiratory Medicine Case Reports, 2015
- Pharmacokinetics and Pharmacodynamics of Antibacterial AgentsInfectious Disease Clinics of North America, 2009
- Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysisEuropean Respiratory Journal, 2009
- Severe acute respiratory syndrome in surgical patients: a diagnostic dilemmaAnz Journal of Surgery, 2005
- Increase in Methicillin-Resistant Staphylococcus aureus Acquisition Rate and Change in Pathogen Pattern Associated with an Outbreak of Severe Acute Respiratory SyndromeClinical Infectious Diseases, 2004
- Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 casesJournal of Infection, 2004
- Lung pathology of fatal severe acute respiratory syndromeThe Lancet, 2003
- Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trialBMJ, 1995